Drug - Publications - Faculty & Research - Harvard Business School

Filter Results: (999)

Filter Results: (999)

Show Results For

← Page 11 of 999 Results →

February 2024
Article

Representation and Extrapolation: Evidence from Clinical Trials

By: Marcella Alsan, Maya Durvasula, Harsh Gupta, Joshua Schwartzstein and Heidi L. Williams

This article examines the consequences and causes of low enrollment of Black patients in clinical trials. We develop a simple model of similarity-based extrapolation that predicts that evidence is more relevant for decision-making by physicians and patients when it... View Details

Keywords: Representation; Racial Disparity; Health Testing and Trials; Race; Equality and Inequality; Innovation and Invention; Pharmaceutical Industry

Find at Harvard

June 2004 (Revised June 2006)
Supplement

Vertex Pharmaceuticals: R&D Portfolio Management (A)

By: Gary P. Pisano, Lee Fleming and Eli Strick

Vertex Pharmaceuticals, Inc., a drug discovery company that recently decided to pursue a vertically integrated business model, chose to build up its clinical development and commercial capabilities and infrastructure. For the first time in its history, Vertex will... View Details

Keywords: Research and Development; Investment Portfolio; Pharmaceutical Industry

2023
Working Paper

Market Exclusivity and Innovation: Evidence From Antibiotics

By: Edward Kong and Olivia Zhao

The US incentivizes drug innovation via patents as well as market exclusivity periods awarded by the US Food and Drug Administration. We estimate the causal effects of extending market exclusivity for an important drug class: antibiotics. Using a... View Details

Keywords: Health Testing and Trials; Innovation and Invention; Motivation and Incentives; Government Administration; Government Legislation; Pharmaceutical Industry; United States

March 2008
Case

The Multiple Sclerosis Center of Atlanta

By: Regina E. Herzlinger and Alfred Martin

The Multiple Sclerosis Center of Atlanta wishes to expand beyond Georgia. The factors influencing this decision are discussed, including drug treatments currently available, and the impact of future drugs in the FDA pipeline as well as financing issues. View Details

Keywords: Decision Choices and Conditions; Financing and Loans; Health Care and Treatment; Health Disorders; Medical Specialties; Expansion; Health Industry; Atlanta

Find at Harvard

30 Mar 2023
Video

Recognizing Market Failure and Options to Address It

August 2001
Case

Pharmaceutical Industry and the AIDS Crisis in Developing Countries, The

Explores the controversy over the pricing of AIDS drugs in poor countries. This issue has received wide publicity due to two events: 1) a court case in South Africa that seeks to force drug companies to license their patents and 2) the announcement by the Indian... View Details

Keywords: Competition; Developing Countries and Economies; Business and Government Relations; Pharmaceutical Industry; South Africa; India

August 2001 (Revised March 2008)
Case

Helios Health (A)

By: Regina E. Herzlinger and Alfred Martin

Helios PC system provides personalized drug information to the patients in the doctor's waiting room. It has met with considerable consumer acceptance and a very high return for the drug companies that sponsor it. What price should it charge them for the service? View Details

Keywords: Entrepreneurship; Price; Health Care and Treatment; Information Publishing; Innovation and Invention; Product Marketing; Demand and Consumers; Health Industry; Pharmaceutical Industry

Find at Harvard

September 1991 (Revised August 1994)
Background Note

Note on Pharmaceutical Industry Regulation

By: Willis M. Emmons III

Traces the evolution of U.S. regulatory policy towards the pharmaceutical industry over the course of the twentieth century. A major theme is the steady shift away from a policy of 'let the buyer beware' to the creation of a complex and time-consuming review process,... View Details

Keywords: Safety; Industry Growth; Marketing; Research and Development; Health Testing and Trials; Economics; Pharmaceutical Industry; United States

Find at Harvard

Research Summary

Regulatory negotiations and risk communication

In the pharmaceutical industry a drugs benefits and risks are constantly being weighed by companies, regulators, physicians and drug consumers. While companies and regulators must make decisions based on population statistics about drug outcomes, physicians and drug... View Details

October 2013
Case

FasterCures: Removing Barriers to Treatments

By: Richard G. Hamermesh and James Weber

In mid-2013, as FasterCures celebrated its 10th anniversary as a center of the Milken Institute, Executive Director Margaret Anderson thought about what the organization should do to ensure it had even more impact in its next 10 years. FasterCures was a non-profit... View Details

January 2021 (Revised June 2021)
Case

Hester Pharmaceuticals (A): A Pricing Dilemma

By: Dante Roscini and John Masko

In August 2019, the leadership of Hester Pharmaceuticals (Hester) had a problem. Italy promised to be a key market for their new breakthrough oncology drug Akrozumab, but for almost two years, its single-payer healthcare system had been unable to agree with Hester on a... View Details

Keywords: Macroeconomics; Trade; Price; Global Range; Global Strategy; Globalized Markets and Industries; Health Care and Treatment; Patents; Monopoly; Negotiation; Business and Government Relations; Risk and Uncertainty; Human Needs; Business Strategy; Commercialization; Pharmaceutical Industry; Italy

04 Jan 2011
News

At Novartis, a winning formula

September 2017
Case

Dr. William Carson— Intrapreneurial Innovation in the Pharmaceutical Industry

By: Steven Rogers and Alyssa Haywoode

Dr. William Carson, an African-American alum of Harvard University became the President and CEO of a multi billion dollar division of Otsuka, a Japan based pharmaceutical company. His ascension to this leadership position followed a thriving career in academic medicine... View Details

Keywords: Dr. Williams Carson; Otsuka America Pharmaceutical; Harvard; Abilify; Aripiprazole; Health Testing and Trials; Globalized Firms and Management; Globalized Markets and Industries; Cross-Cultural and Cross-Border Issues; Decision Choices and Conditions; Pharmaceutical Industry; Japan

October 2023
Article

What Does the Inflation Reduction Act Mean for Patients and Physicians?

By: Amitabh Chandra and Benedic Ippolito

The debate around prescription drug measures in the recently passed U.S. Inflation Reduction Act (IRA), which limit some patients’ out-of-pocket costs, has not fully addressed their effect on physicians and patients via their effect on payers. Reducing patients’ costs... View Details

Keywords: Government Legislation; Price; Health Care and Treatment

Find at Harvard

November 2019 (Revised April 2020)
Technical Note

The Life Sciences Revolution: A Technical Primer

By: Gary P. Pisano, William J. Anderson, Amitabh Chandra, Clarissa Ceruti and Stephanie Oestreich

For more than two decades, scientific advances have been driving profound changes in drug discovery and the drug industry itself. This case provides an overview and description of these technical and scientific advances. Written for the nonscientific reader, it may be... View Details

Keywords: Science; Technological Innovation; Technology; Pharmaceutical Industry; Biotechnology Industry

19 Dec 2016
News

Dr. Lauren Cohen Breaks All Time Squat Record

14 Dec 2020
Research & Ideas

What Does December's Drug-Approval Dash Mean for COVID-19 Vaccines?

Pharmaceutical regulators around the world tend to speed through drug applications in December and before major national holidays, according to new research that might raise questions about COVID-19 vaccines and other treatments under... View Details

Keywords: by Danielle Kost; Pharmaceutical; Health

November 2024
Article

The Health Costs of Cost Sharing

By: Amitabh Chandra, Evan Flack and Ziad Obermeyer

What happens when patients suddenly stop their medications? We study the health consequences of drug interruptions caused by large, abrupt, and arbitrary changes in price. Medicare’s prescription drug benefit as-if-randomly assigns 65-year-olds a drug budget as a... View Details

Keywords: Outcome or Result; Health Care and Treatment; Budgets and Budgeting; Cost

June 1999 (Revised October 1999)
Case

Eli Lilly, 1998 (A): Strategic Challenges

By: Michael Y. Yoshino and Thomas W. Malnight

Deals with key strategic challenges facing Eli Lilly, a highly successful U.S.-based drug company. View Details

Keywords: Problems and Challenges; Strategy; Pharmaceutical Industry

March 2015 (Revised September 2016)
Case

Terrapin Laboratory

By: Richard G. Hamermesh and Joseph B. Fuller

Describes the formation and rapid growth of a drug testing company. The company needs to decide whether to enter the painkiller testing market, in addition to growing its drug treatment center business. The associated teaching materials provide students the opportunity... View Details

Keywords: Business Growth; Entrepreneurial Management; Entrepreneurship; Growth Strategy; Market Entry; Venture Capital; Growth Management; Expansion; Financing and Loans; Health Care and Treatment; Health Testing and Trials; Business Startups; Pharmaceutical Industry; Health Industry

←
11
12
…
49
50
→